What did the Mounjaro weight loss trials find?

What exactly was tested in the Mounjaro weight loss trials?

The SURMOUNT programme was a series of phase 3 randomised controlled trials designed to evaluate tirzepatide specifically for weight management, separate from the earlier SURPASS diabetes trials. SURMOUNT-1 is the cornerstone: 2,539 adults with a body-mass index of 30 or above (or 27-plus with at least one weight-related condition), without type 2 diabetes, were allocated to 5 mg, 10 mg or 15 mg tirzepatide weekly, or placebo, for 72 weeks alongside reduced-calorie diet and increased physical activity.

The design mattered. Participants had real-world comorbidities (hypertension, high cholesterol, obstructive sleep apnoea) and the trial was large enough to give regulators confidence in both the efficacy and the safety signal. If you've spent time on the tirzepatide trials overview, you'll recognise why the SURMOUNT programme was what eventually secured UK licensing.

SURMOUNT-2 extended this to adults with type 2 diabetes. SURMOUNT-5, the most recent, was an open-label head-to-head comparison with semaglutide 2.4 mg weekly over 72 weeks in 751 adults with obesity but no diabetes, a design deliberately chosen to pit the two leading GLP-1-class medicines against each other directly. The SURMOUNT-1 paper in the New England Journal of Medicine remains the primary evidence document cited by NICE.

How large were the weight losses, and which dose produced them?

At the 5 mg dose, average weight reduction in SURMOUNT-1 was around 15%. At 10 mg, roughly 19.5%. At 15 mg, approximately 20–21%, with some analyses reaching around 22.5%, figures that had not been seen before in a licensed injectable for weight management in people without diabetes. Those are group averages, meaning some participants lost considerably more and some less.

The 72-week timeframe is worth noting. Weight loss was not uniform across the trial: the steepest reduction typically came in the first six months, with a plateau as the body adjusted and the dose reached its maintenance level. If you want the full breakdown of what different doses achieved and how the titration schedule plays into that, the tirzepatide weight loss percentage trials page covers it in more depth.

SURMOUNT-5's head-to-head finding (greater average loss with tirzepatide than with semaglutide 2.4 mg) is significant because it provides direct comparative evidence rather than cross-trial inference. If you want to understand how these results are being interpreted in a UK context, our Mounjaro trials UK page looks at exactly that. The NICE technology appraisal TA1026 is the regulator's published assessment of all this evidence and the basis for the current UK recommendation.

What did the trials say about who responds, and who was excluded?

Here is something people often find surprising, and genuinely worth sitting with: the SURMOUNT-1 participants with the highest baseline BMI did not consistently produce the largest percentage losses. Response varied across individuals in ways that baseline characteristics alone didn't fully predict. The trials excluded people with a history of pancreatitis, certain gastrointestinal conditions, medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Pregnancy, breastfeeding and the intention to conceive were also exclusion criteria, a reflection of the fact that the medicine is not recommended during these periods. People under 18 were not included; tirzepatide is licensed for adults only. These exclusions from the research directly shape which patients a prescriber can safely treat today.

The ethnic-background adjustments in NICE's guidance (BMI thresholds 2.5 kg/m² lower for some backgrounds) were informed partly by evidence about differential metabolic risk at equivalent BMI, though this sits more in the NICE committee's deliberation than in the trial design itself. For more detail on how eligibility translates to a UK private setting, the Mounjaro weight loss page sets that out clearly.

What happened to participants after the trial ended?

One finding from extension and withdrawal phases deserves plain acknowledgement: when tirzepatide was stopped, participants regained a substantial portion of the weight lost. This is consistent with what obesity science has shown across multiple medicines and reinforces that weight management treatment is not a short course in the way antibiotics are. The underlying biology driving weight regain reasserts itself when the pharmacological effect is removed.

This matters for how you think about the trials' results. A 20% average weight loss over 72 weeks is a robust finding, but it is a finding about what happens during treatment, not a statement about permanent change independent of it. For a broader look at how Mounjaro sits within a longer-term weight management strategy, the Mounjaro overview is a good starting point, and if you're also interested in how the branded version compares to other formulations of the same molecule, our Alluvi tirzepatide page explains the differences. Understanding the evidence properly is, honestly, the part most people wish they'd spent more time on before starting any treatment. A prescriber can help you apply these trial findings to your own situation. If you'd like that conversation, you can check your eligibility with our clinical team.